Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

Spontaneous loss of hepatitis B e antigen (HBeAg) followed by seroconversion to anti-HBe usually coincides with normalization of serum alanine aminotransferase (ALT) levels, reduction in HBV DNA ...

In this study, we answered two major questions that relate to use of transgenic plants for oral hepatitis B vaccines. First, we showed that an antigen from a non-enteric human pathogen (HBV ...

Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

Hepatitis B is a liver infection that inflames the organ ... "They do so by exposing the body to an active ingredient called an antigen which triggers an immune response," Brull says.

These Phase 1b data, in 34 chronically infected hepatitis B patients, on nucleos(t ... declines in HBV surface antigen (HBsAg) ranging from -2.3 to -0.4 log10 IU/mL were observed in 7 patients ...

Previously, the company said the investigational combo reduced hepatitis B surface antigens—one of the study’s four primary endpoints. At the time, Vir said it would not be moving the asset ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor (XNCR) and Alnylam (ALNY). Read more here.

The WHO recommends vaccination against 12 deadly diseases in childhood, but how long does protection last, and how do they ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks' treatment to below the lower limit of detection ...

bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants ...